AP NEWS

Pituitary ACTH Hypersecretion (Cushing’s Disease) - Pipeline Insight, 2018 - ResearchAndMarkets.com

September 14, 2018

DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The “Pituitary ACTH Hypersecretion (Cushing’s Disease) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Pituitary ACTH Hypersecretion (Cushing’s Disease) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Scope

The report provides a snapshot of the pipeline development for Pituitary ACTH Hypersecretion (Cushing’s Disease) The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Pituitary ACTH Hypersecretion (Cushing’s Disease) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Pituitary ACTH Hypersecretion (Cushing’s Disease) The report also covers the dormant and discontinued pipeline projects related to Pituitary ACTH Hypersecretion (Cushing’s Disease)

Companies Featured

Amryt Pharma PLC Crinetics Pharmaceuticals, Inc. Cyclacel Pharmaceuticals, Inc. Millendo Therapeutics, Inc. Novartis AG Pfizer Inc. Strongbridge Biopharma PLC

Key Topics Covered

1. Report Introduction

2. Pituitary ACTH Hypersecretion (Cushing’s Disease) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Pituitary ACTH Hypersecretion (Cushing’s Disease)

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m49f9x/pituitary_acth?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005360/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 10:54 AM/DISC: 09/14/2018 10:54 AM

http://www.businesswire.com/news/home/20180914005360/en

AP RADIO
Update hourly